Then, the patient was admitted to our hospital with high-grade fever, significant short of breath, sputum production, conjunctival hemorrhage, purpura, yellow discoloration of the skin and sclera, tachycardia, and edema on the extremities. Laboratory examination showed mild anemia, agranulocytosis, thrombocytopenia, bilirubinemia, elevation of aminotransferase, hypertriglyceridemia, hypofibrinogenemia, and elevated ferritin. Cellular immunologic test showed marked reduction of CD4 to 9.6 × 10 10 cells/m 3 . Abdominal ultrasound showed splenomegaly. The patient was diagnosed with HLH according to the 2004 HLH diagnostic criteria. Percutaneous lung biopsy specimens and sputum sample both isolated Nocardia asiatica sp. nov [ Figure 1c and 1d]. The patient was diagnosed as pulmonary nocardiosis and secondary HLH.
Then, the issues turned to the treatment since the therapeutic strategies for pulmonary nocardiosis and HLH were contradictory. During the 1 st week, the patient was treated with methylprednisolone sodium succinate and γ-globulin for HLH. Symptoms such as fever, hemorrhage, and yellow discoloration of the skin and sclera improved, as well as those laboratory abnormalities. Then, oral administration of trimethoprim/sulfamethoxazole (TMP/SMX) and intravenous administration of imipenem and amikacin were added for pulmonary nocardiosis. With the continuous improvement of symptoms, the antibiotic therapy was switched to oral administration of TMP/SMX and minocycline. After eight weeks of treatment, the follow-up CT showed significant resolution of ground-glass infiltration and nodules [ Figure 1e ]. Then, the dosage of corticosteroid was tapped slowly. treatments with corticosteroids or cytotoxic therapy are at a high risk for Nocardi infection. [1] A retrospective study showed that the most common risk factor for both pulmonary and disseminated nocardiosis was corticosteroid therapy. [2] Dose and duration of steroid treatment in nocardiosis patients receiving corticosteroids prior to diagnosis varied widely.
Nocardial infections range from minor cutaneous lesions to severe pulmonary or systemic nocardiosis, including central nervous system dissemination. [3] Pulmonary nocardiosis is the most common clinical presentation of infection because inhalation is the primary route of bacterial exposure. The clinical presentation of pulmonary nocardiosis is variable and nonspecific. Moreover, the chest radiologic manifestation can also be variable. Consolidations and large irregular nodules, often with cavity formation, are most common; nodules, masses, and interstitial patterns also occur. Since the clinical and radiologic manifestations are nonspecific, and the microbiological diagnosis is often difficult, pulmonary nocardiosis can be mistaken for other infections in some patients, such as tuberculosis, bacterial pneumonia, or malignancies.
In addition, the patient had a secondary HLH after pulmonary nocardiosis. HLH is an immune-mediated life-threatening disease. It is a rare disease and is divided into primary and secondary. Most causes of secondary HLH are viral, autoimmune, or neoplasia related. [4] Pulmonary nocardiosis has rarely been reported as a cause of HLH. Pulmonary nocardiosis shows a broad and variable clinical manifestation. Etiological diagnosis needs experienced clinical microbiology doctors. Etiological treatment is more important for a patient with infection-associated HLH.
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